Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Sifalimumab in SLE
NCT00657189Phase 2Completed
- Sponsor
- MedImmune
- Start
- Jul 2008
- Primary completion
- May 2010
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sifalimumab in systemic lupus erythematosus (SLE), sponsored by MedImmune. Started Jul 2008; status: completed.
02
Drugs
sifalimumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT00657189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00657189.